Venture Visionary Partners LLC Raises Holdings in Johnson & Johnson (NYSE:JNJ)

Venture Visionary Partners LLC grew its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 282.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 379,387 shares of the company's stock after purchasing an additional 280,072 shares during the period. Johnson & Johnson makes up approximately 1.6% of Venture Visionary Partners LLC's holdings, making the stock its 10th largest holding. Venture Visionary Partners LLC's holdings in Johnson & Johnson were worth $54,881,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of JNJ. Oregon Pacific Wealth Management LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $949,000. Horan Securities Inc. increased its position in shares of Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after purchasing an additional 90 shares in the last quarter. Strategic Financial Concepts LLC lifted its holdings in Johnson & Johnson by 57.9% during the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock valued at $501,000 after purchasing an additional 1,271 shares during the last quarter. Lord Abbett & CO. LLC acquired a new position in Johnson & Johnson in the third quarter valued at about $69,859,000. Finally, Quantinno Capital Management LP grew its stake in Johnson & Johnson by 29.0% during the third quarter. Quantinno Capital Management LP now owns 219,599 shares of the company's stock worth $35,588,000 after buying an additional 49,307 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Up 2.9 %

Shares of NYSE:JNJ traded up $4.54 during midday trading on Thursday, hitting $159.90. The company had a trading volume of 13,243,050 shares, compared to its average volume of 7,757,538. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The firm has a fifty day simple moving average of $159.63 and a 200 day simple moving average of $156.01. The stock has a market cap of $385.33 billion, a price-to-earnings ratio of 24.04, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company's revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business earned $2.29 earnings per share. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research analyst reports. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday. Wells Fargo & Company reduced their price objective on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. Stifel Nicolaus decreased their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a report on Thursday, January 23rd. Barclays lifted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a report on Tuesday, January 28th. Finally, Leerink Partners lowered their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $171.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.